Ofichem Acquired Kinentia to Enter U.S. Market
The acquisition grants the Dutch manufacturer a U.S. base to integrate Kinentia's early-stage development services.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Should the US government restrict the acquisition of domestic biotech firms by foreign corporations?
Dutch contract development firm Ofichem has signed a definitive agreement to acquire New York-based Kinentia Biosciences. The deal creates a cross-continental footprint by pairing Ofichem's European production with Kinentia's domestic development capacity.
Why it matters
For operators, this deal signifies a push to shorten supply chains by localizing early-stage drug development within the U.S. market. It allows the group to offer end-to-end services, from initial substance development in New York to large-scale European manufacturing.
The deal brings together two contract development and manufacturing organizations in an acquisition with no financial terms disclosed. The exact valuation and deal size remain undisclosed.
The players
Ofichem
A Dutch contract development and manufacturing organization with established production capabilities in Europe.
Kinentia Biosciences
A drug substance contract development and manufacturing organization based in Rensselaer, New York.
The details
The transaction leverages Kinentia's existing New York facility to establish a direct operational foothold for Ofichem in the United States. By integrating the two firms, the group intends to bridge early-stage research and development with its established, large-scale European manufacturing infrastructure. The deal is currently pending approval from the Committee on Foreign Investment in the United States (CFIUS) and remains subject to other customary closing conditions.
Timeline
October 6, 2026: Ofichem and Kinentia Biosciences signed the acquisition agreement.
Market Landscape
This acquisition follows a broader industry trend of foreign service providers acquiring U.S.-based capacity to secure local market access. The deal is currently subject to the Committee on Foreign Investment in the United States (CFIUS) review process.
Operators in the drug development space should monitor this consolidation as a signal that international manufacturers are prioritizing U.S.-based R&D assets. Consult with qualified counsel regarding how CFIUS reviews may affect deal timelines for international acquisitions.
The takeaway
This merger signals an increasing focus on integrated, cross-border development pipelines to capture value across the drug lifecycle. Operators should track the closing of this deal to see how international competitors adjust their domestic service offerings in the coming year.
Further reading
For broader trends in the pharmaceutical service sector, visit Healthcare.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Should the US government restrict the acquisition of domestic biotech firms by foreign corporations?
